Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet

Nightingale Health

2,78

 

EUR

4 590 följer bolaget

HEALTH

NASDAQ Helsinki

Medicinsk Utrustning & Service

Hälsovård

Översikt
Nyckeltal & Estimat
Investerarkonsensus
Jämför
−2,63%
−7,02%
−4,47%
−3,47%
−9,15%
+70,55%
+57,24%
-
−46,02%

Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.

Läs mera
Börsvärde
169,38 mn EUR
Omsatt (värde)
-
P/E (just.) (25e)
−10,37
EV/EBIT (adj.) (25e)
−6,64
P/B (25e)
2,44
EV/S (25e)
22,08
Direktavkastnings- % (25e)
-
Coverage
Rekommendation
Öka
Riktkurs
2.90 EUR
Uppdaterad
2025-03-07
Disclaimer
Antti Luiro
Antti Luiro

Head of Nordic ER Development, Analyst

Senaste analysen

Latest analysis report

Released: 2025-03-07

Latest extensive report

Released: 2023-06-05

Omsättning & EBIT-%

Omsättning mn

EBIT-%

Vinst per aktie & Utdelning

EPS (adj.)

Direktavkastning

Risk
Business risk
Valuation risk
Låg
Hög
Alla
Analys
Webcasts
Pressmeddelanden
VisarAlla typer av innehåll
Regulatoriskt pressmeddelande2025-05-02 13:45

Changes in Nightingale Health Plc’s Management Team

Nightingale Health
Regulatoriskt pressmeddelande2025-04-23 15:15

Conversion of Nightingale Health Plc’s Series A shares to Series B shares

Nightingale Health
Pressmeddelande2025-04-10 06:30

Nightingale Health’s laboratory implementation in the United States progresses as planned – opens first to medical research customers in Summer 2025

Nightingale Health

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

Inderes användarkonto
Ger dig möjlighet att följa bolag och beställa notifikationer
Tillgång till analytikerkommentarer och rekommendationer
Tillgång till vårt aktiescreeningsverktyg och andra populära verktyg
Skapa användarkonto
Regulatoriskt pressmeddelande2025-03-21 11:00

Trading in Nightingale Health's B shares and ADRs begins on 21 March 2025 on the OTCQX International Market in the US

Nightingale Health
Regulatoriskt pressmeddelande2025-03-18 09:30

Nightingale Health Plc's listing application has been approved and trading in its Series B shares on the Main Market of Nasdaq Helsinki will commence on 19 March 2025

Nightingale Health
Analytikerkommentar2025-03-18 06:59 av
Antti Luiro

Nightingale OTC trading in the US likely to start already within a week

The news is expected, although OTC trading will start sooner than expected after the move to the main list.

Nightingale Health
Regulatoriskt pressmeddelande2025-03-17 14:15

The Finnish Financial Supervisory Authority has approved Nightingale Health Plc's Finnish prospectus

Nightingale Health
Regulatoriskt pressmeddelande2025-03-17 11:55

Nightingale Health establishes ADR program in the US - trading in Company's B shares and ADRs begins on 19 March 2025, at the earliest, and 24 March 2025, at the latest, on the OTCQX Market in the US

Nightingale Health
Analytikerkommentar2025-03-13 06:16 av
Antti Luiro

Nightingale applies for its shares to be listed on the Main Market of Nasdaq Helsinki

The submission of the application for moving to the main list was expected, as the company announced in November that it was looking into it.

Nightingale Health
Regulatoriskt pressmeddelande2025-03-12 12:30

Nightingale Health Plc applies for its series B shares to be listed on the Main Market of Nasdaq Helsinki

Nightingale Health
Nightingale H1'FY25: Blood draws again
Aktieanalys2025-03-07 09:45 av
Antti Luiro

Nightingale H1'FY25: Blood draws again

Nightingale is just launching the commercial phases with its second and third healthcare partners. The company's comments on the sales pipeline are also promising, and we believe it will announce at least one significant partnership during the current year.

Nightingale Health
Nightingale, Webcast, Q2'25
Webcast2025-03-06 12:00

Nightingale, Webcast, Q2'25

Nightingale Health
Regulatoriskt pressmeddelande2025-03-06 07:00

Nightingale Health's half-year report: International expansion continues in Southeast Asia and the United States

Nightingale Health
Nightingale H1’FY25 preview: Maturing the next wave of pilots
Analytikerkommentar2025-03-05 07:38 av
Antti Luiro

Nightingale H1’FY25 preview: Maturing the next wave of pilots

Driven by the Terveystalo partnership, which was successfully launched at the beginning of 2024, revenue is on an upward trend compared to the previous year.

Nightingale Health
Pressmeddelande2025-02-28 10:35

Nightingale Health to publish half-year report for July - December 2024 on 6 March 2025

Nightingale Health
Pressmeddelande2025-02-27 12:15

Nightingale Health announces the development of innovative LLM based tool to empower anyone to take informed decisions to lower disease risks

Nightingale Health
Analytikerkommentar2025-02-10 07:42 av
Antti Luiro

Nightingale's path to regulatory approval in the US is becoming clearer and progressing

As promised, Nightingale provided further information on plans to obtain regulatory approvals in the US on Friday.

Nightingale Health
Pressmeddelande2025-02-07 12:15

Nightingale Health announces its updated regulatory plan in the United States

Nightingale Health
Analytikerkommentar2025-01-27 10:47 av
Antti Luiro

Nightingale Health enters Middle East collaboration

Nightingale has signed a pilot agreement and letter of intent with Enigma Genomics to use the company's Remote Health Check in a full-scale commercial operation for Enigma's clients in Saudi Arabia and the wider MENA region.

Nightingale Health
Pressmeddelande2025-01-27 07:00

Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region

Nightingale Health
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Our team
  • Inderes som en investering
  • Tjänster för börsbolag
Our platform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.